GlassScriptPhysician profile
Riolin C Andrade
NPI 1780686071
$2,339.83
in general payments reported to CMS, 2019-2025
29 companies · $46.74 in 2025
The $46.74 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $136 · 2021: $194 · 2022: $123 · 2023: $110 · 2024: $215 · 2025: $46.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.57 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $286.06 | 2019-2020 | |
| Celgene Corporation | $277.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $186.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $178.09 | 2019-2025 | |
| Clovis Oncology, INC. | $130.64 | 2019 | |
| Progenics Pharmaceuticals, INC. | $125.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.63 | 2019-2021 | |
| Beigene USA, INC. | $109.51 | 2023 | Brukinsa |
| Incyte Corporation | $99.95 | 2022 | |
| Janssen Biotech, INC. | $98.56 | 2019-2021 | |
| Pfizer INC. | $92.65 | 2019 | |
| Abbvie INC. | $88.66 | 2019 | |
| Tempus Ai, INC | $84.61 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $73.38 | 2019 | |
| Merck Sharp & Dohme LLC | $63.44 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $46.25 | 2019 | |
| Daiichi Sankyo INC. | $42.26 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $40.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.48 | 2019 | |
| Genzyme Corporation | $21.27 | 2019 | |
| Seagen INC. | $19.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.77 | 2019 | |
| Eisai INC. | $17.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Kite Pharma, INC. | $16.66 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $14.27 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Astellas Pharma US INC | $11.50 | 2019 | |
| Gilead Sciences, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riolin Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.